Key result
GLP-1RAs linked to improved eGFR slope in high-risk diabetic nephropathy.
Why the study?
Factors contributing to improvement in eGFR slope following intensive treatment in diabetic nephropathy patients at high risk of progression were not well defined.
Does intensive treatment improve eGFR slope in patients with diabetic nephropathy at high risk of disease progression?
Cohort (n=64)
No
Does intensive treatment improve eGFR slope in patients with diabetic nephropathy at high risk of disease progression?
Effect estimate: Coefficient -6.43 (95% CI -10.17 to -2.70)
p-value: p=<0.01
May inform strategies to improve eGFR in high-risk diabetic nephropathy; hypothesis-generating and should not yet change practice.
Objective: To explore the factors that contribute to the improvement in the annual change in the estimated glomerular filtration rate (eGFR slope) in patients with diabetic nephropathy at high risk of disease progression, particularly those with an eGFR of less than 30 mL/min/1.73 m2.
No takes yet. Share an insight, caveat, or question.
Kiku et al. (2026) conducted a cohort in Diabetic nephropathy (n=64). GLP-1RAs vs. Other treatments (ARBs, SGLT2i, or none) was evaluated on eGFR slope (annual change in eGFR) (Coefficient -6.43, 95% CI -10.17 to -2.70, p=<0.01). Treatment with GLP-1RAs was significantly associated with an improvement in eGFR slope in patients with diabetic nephropathy at high risk of disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: